Benitec Biopharma Inc. (BNTC) vs Sanara MedTech Inc. (SMTI)
A side-by-side comparison of Benitec Biopharma Inc. and Sanara MedTech Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BNTC
Benitec Biopharma Inc.
$9.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SMTI
Sanara MedTech Inc.
$35.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BNTC vs SMTI
growth of $100 · dividends reinvested · last 10yBNTC -97.4% (-30.5%/yr)SMTI +775.0% (+24.2%/yr)SMTI compounded faster over this window
Log scale — wide-divergence pair
BNTC SMTI
BNTC vs SMTI: by the numbers
- •SMTI is the larger company ($322M vs $309M market cap).
- •Both run net losses; BNTC's is the smaller (0.00% vs -29.15% net margin).
Metrics side by side
Valuation
| Metric | BNTC | SMTI |
|---|---|---|
| Forward P/E | N/A | 184.21 |
| P/S ratio | N/A | 2.93 |
| P/B ratio | 1.75 | 40.51 |
| EV / EBITDA | N/A | 27.80 |
| FCF yield | N/A | 1.40% |
Profitability
| Metric | BNTC | SMTI |
|---|---|---|
| Gross margin | 0.00% | 91.33% |
| Operating margin | 0.00% | 9.36% |
| Net margin | 0.00% | -29.15% |
| ROE | -25.73% | -403.03% |
| ROIC | -28.88% | 18.15% |
Growth (annualized)
| Metric | BNTC | SMTI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 40.06% |
| Total return CAGR (5Y) | -31.08% | 0.35% |
Frequently asked
- How have BNTC and SMTI total returns compared?
- Over the past 10 years, BNTC delivered -30.49% and SMTI delivered 24.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Benitec Biopharma ROESanara MedTech ROEBenitec Biopharma operating marginSanara MedTech operating marginBenitec Biopharma revenue growthSanara MedTech revenue growthBenitec Biopharma free cash flowSanara MedTech free cash flow
Benitec Biopharma & Sanara MedTech appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.